“It ain’t Christmas until James Bond escapes Piz Gloria.”

Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
Global Afamelanotide Market is expected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1% during 2025–2032. Market expansion is fueled by rising cases of rare phototoxic disorders such as Erythropoietic Protoporphyria (EPP), increased awareness about orphan diseases, and advancements in melanocortin-based peptide therapies.Afamelanotide, marketed as SCENESSE®, is the first and only FDA- and EMA-approved treatment for EPP. By stimulating melanin production, it offers significant photoprotection and improves sunlight tolerance, making it a breakthrough therapy for patients suffering from severe light sensitivity. Clinical pipelines exploring applications in vitiligo, photodermatoses, and select neurological disorders are further expanding market potential.

Stealth bomber caught on google maps - 39 01 18.5N 93 35 40.5W

We had some surprisingly friendly guests visiting our camp site

Global Afamelanotide Market (2024–2032): USD 136.27M to USD 258.01M Growth at 9.1% CAGR
Global Afamelanotide Market is projected to grow from USD 136.27 million in 2024 to USD 258.01 million by 2032, registering a strong CAGR of 9.1%. Afamelanotide (SCENESSE®), the first approved treatment for EPP, enhances melanin production to improve sunlight tolerance in patients with severe phototoxic disorders. Rising awareness of rare diseases, expanding clinical trials in vitiligo and photodermatoses, and broader regulatory support are fueling market demand globally.